(VTR) Ventas - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92276F1003

Senior Housing, Medical Buildings, Research Centers

Stock: Health Care REITs
Age 27.7y

MCap 36,851m
Avg Vol 2.51M (193M USD)

Beta 0.233
Volatility 19.03%

EPS (Earnings per Share)

EPS CAGR: -8.86%
EPS Trend: 34.1%

Last SUE: -0.94
Qual. Beats: 0

Revenue

Rev. CAGR: 10.54%
Rev. Trend: 97.5%

Last SUE: 3.72
Qual. Beats: 5

Dividends

Dividend Yield	2.77%
Yield on Cost 5y	4.75%
Yield CAGR 5y	1.63%
Payout Consistency	96.7%
Payout Ratio	3.8%

Risk via 5d forecast
Volatility	19.0%
Value at Risk 5%th	29.5%
Relative Tail Risk	-5.71%

Reward TTM
Sharpe Ratio	1.21
Alpha	28.88
CAGR/Max DD	0.85

Character TTM
Hurst Exponent	0.350
Beta	0.233
Beta Downside	0.353

Drawdowns 3y
Max DD	22.88%
Mean DD	7.37%
Median DD	6.09%

Description: VTR Ventas December 17, 2025

Ventas, Inc. (NYSE: VTR) is a S&P 500-listed REIT that focuses on senior housing, outpatient medical facilities, research centers, and other healthcare-related properties across North America and the United Kingdom. With roughly 1,400 assets-including more than 850 senior-living communities-the company positions itself as a core participant in the “longevity economy,” aiming to generate superior returns through operational expertise, data-driven insights from its Ventas OI platform, and a strong balance sheet.

Key metrics that analysts watch include a FY 2023 adjusted funds from operations (AFFO) growth of about 5% YoY, an occupancy rate that has steadied near 94% across its senior-housing portfolio, and a dividend yield hovering around 5.2%, which is attractive in a low-interest-rate environment. The sector’s performance is also driven by macro trends such as the U.S. aging population-projected to add ~10 million people over 65 by 2030-and the continued shift toward outpatient care, which compresses cap rates for high-quality healthcare REITs.

For a deeper dive into VTR’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income: 238.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.19 > 1.0
NWC/Revenue: -8.89% < 20% (prev 6.51%; Δ -15.40% < -1%)
CFO/TA 0.06 > 3% & CFO 1.55b > Net Income 238.0m
Net Debt (12.60b) to EBITDA (2.15b): 5.87 < 3
Current Ratio: 0.63 > 1.5 & < 3
Outstanding Shares: last quarter (463.4m) vs 12m ago 10.48% < -2%
Gross Margin: 41.97% > 18% (prev 0.43%; Δ 4154 % > 0.5%)
Asset Turnover: 21.25% > 50% (prev 18.94%; Δ 2.31% > 0%)
Interest Coverage Ratio: 1.07 > 6 (EBITDA TTM 2.15b / Interest Expense TTM 752.5m)

Altman Z'' (< 1.1 .. > 2.6) -1.87

A: -0.02 (Total Current Assets 849.3m - Total Current Liabilities 1.34b) / Total Assets 26.93b
B: -0.27 (Retained Earnings -7.37b / Total Assets 26.93b)
C: 0.03 (EBIT TTM 808.6m / Avg Total Assets 26.14b)
D: -1.01 (Book Value of Equity -14.66b / Total Liabilities 14.50b)
Altman-Z'' Score: -1.87= D

ValueRay F-Score (Strict, 0-100) 60.41

1. Piotroski: 4.0pt
2. FCF Yield: 2.33%
3. FCF Margin: 20.74%
4. Debt/Equity: 1.03
5. Debt/Ebitda: 5.87
6. ROIC - WACC: -2.90%
7. RoE: 2.06%
8. Revenue Trend: 97.51%
9. EPS Trend: 34.13%

What is the price of VTR shares?

As of January 23, 2026, the stock is trading at USD 77.78 with a total of 3,578,234 shares traded.
Over the past week, the price has changed by +1.12%, over one month by -1.17%, over three months by +11.41% and over the past year by +32.64%.

Is VTR a buy, sell or hold?

Ventas has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy VTR.

Strong Buy: 12
Buy: 5
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the VTR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	85.7	10.1%
Analysts Target Price	85.7	10.1%
ValueRay Target Price	89.9	15.6%

VTR Fundamental Data Overview January 19, 2026

P/E Trailing = 148.0189
P/E Forward = 133.3333
P/S = 6.6469
P/B = 2.981
P/EG = 1.7374
Revenue TTM = 5.56b USD
EBIT TTM = 808.6m USD
EBITDA TTM = 2.15b USD
Long Term Debt = 12.57b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, last quarter)
Debt = 12.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.60b USD (from netDebt column, last quarter)
Enterprise Value = 49.45b USD (36.85b + Debt 12.79b - CCE 188.6m)
Interest Coverage Ratio = 1.07 (Ebit TTM 808.6m / Interest Expense TTM 752.5m)
EV/FCF = 42.91x (Enterprise Value 49.45b / FCF TTM 1.15b)
FCF Yield = 2.33% (FCF TTM 1.15b / Enterprise Value 49.45b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 4.28% (Net Income TTM 238.0m / Revenue TTM 5.56b)
Gross Margin = 41.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 3.22b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 41.80%)
Tobins Q-Ratio = 1.84 (Enterprise Value 49.45b / Total Assets 26.93b)
Interest Expense / Debt = 2.34% (Interest Expense 299.7m / Debt 12.79b)
Taxrate = 21.0% (US default 21%)
NOPAT = 638.8m (EBIT 808.6m * (1 - 21.00%))
Current Ratio = 0.63 (Total Current Assets 849.3m / Total Current Liabilities 1.34b)
Debt / Equity = 1.03 (Debt 12.79b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = 5.87 (Net Debt 12.60b / EBITDA 2.15b)
Debt / FCF = 10.93 (Net Debt 12.60b / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.91% (Net Income 238.0m / Total Assets 26.93b)
RoE = 2.06% (Net Income TTM 238.0m / Total Stockholder Equity 11.53b)
RoCE = 3.35% (EBIT 808.6m / Capital Employed (Equity 11.53b + L.T.Debt 12.57b))
RoIC = 2.61% (NOPAT 638.8m / Invested Capital 24.50b)
WACC = 5.50% (E(36.85b)/V(49.64b) * Re(6.77%) + D(12.79b)/V(49.64b) * Rd(2.34%) * (1-Tc(0.21)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 6.71%
[DCF Debug] Terminal Value 87.44% ; FCFF base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 68.55 (EV 44.80b - Net Debt 12.60b = Equity 32.20b / Shares 469.7m; r=5.90% [WACC]; 5y FCF grow 14.74% → 2.90% )
EPS Correlation: 34.13 | EPS CAGR: -8.86% | SUE: -0.94 | # QB: 0
Revenue Correlation: 97.51 | Revenue CAGR: 10.54% | SUE: 3.72 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=-0.003 | Revisions Net=+3 | Analysts=4
EPS next Year (2026-12-31): EPS=0.56 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+109.3% | Growth Revenue=+14.8%

Additional Sources for VTR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle